Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Yunduan He"'
Autor:
Caiyun Nie, Weifeng Xu, Yanwei Guo, Xiaohui Gao, Huifang Lv, Beibei Chen, Jianzheng Wang, Yingjun Liu, Jing Zhao, Saiqi Wang, Yunduan He, Xiaobing Chen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) and RC48 as thi
Externí odkaz:
https://doaj.org/article/a429df784fe14dd698639c4709778fe0
Autor:
Hui Wang, Caiyun Nie, Weifeng Xu, Jing Li, He Gou, Huifang Lv, Beibei Chen, Jianzheng Wang, Yingjun Liu, Yunduan He, Jing Zhao, Xiaobing Chen
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progres
Externí odkaz:
https://doaj.org/article/eb461969120c41c78b75358b50e2f1a6
Autor:
Huifang Lv PhD, Caiyun Nie PhD, Yunduan He PhD, Beibei Chen PhD, Yingjun Liu PhD, Junling Zhang MD, Xiaobing Chen PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 23 (2024)
Background: Severe delayed diarrhea and hematological toxicity limit the use of irinotecan. Uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1 ) is a critical enzyme in irinotecan metabolism. The study aims to investigate the safety and efficac
Externí odkaz:
https://doaj.org/article/09040aea2b49418e99f1ca765ee56999
Autor:
Junyong Wang, Yaping Guo, Yunduan He, Yifan Qin, Xiuling Li, Ling Yang, Kangdong Liu, Li Xiao
Publikováno v:
Molecular Metabolism, Vol 80, Iss , Pp 101882- (2024)
Objective: Nonalcoholic fatty liver disease (NAFLD) is an emerging public health threat as the most common chronic liver disease worldwide. However, there remains no effective medication to improve NAFLD. G protein-coupled receptors (GPCRs) are the m
Externí odkaz:
https://doaj.org/article/1737f03f782848ca81c6241ba20d2f47
Autor:
Beibei Chen, Huichen Zhao, Jinxi Huang, Huifang Lv, Weifeng Xu, Caiyun Nie, Jianzheng Wang, Jing Zhao, Yunduan He, Saiqi Wang, Xiaobing Chen
Publikováno v:
BMC Geriatrics, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Objective This is the first clinical study that wants to investigate the treatment patterns, clinical outcomes, and prognostic factors of regorafenib plus PD-1 inhibitors therapy in Chinese elderly patients with advanced colorectal cancer. M
Externí odkaz:
https://doaj.org/article/5d5f456452c1435aa6b519a00b80739a
Autor:
Caiyun Nie MD, Huifang Lv MD, Beibei Chen MD, Weifeng Xu MD, Jianzheng Wang MD, Saiqi Wang MD, Yingjun Liu MD, Yunduan He MD, Jing Zhao MD, Xiaobing Chen MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Objectives: This study was carried out to assess the efficacy and drug toxicity of anti-angiogenic tyrosine kinase inhibitor (TKI) plus chemotherapy as second-line or above therapeutic regime in advanced or metastatic gastric cancer patients. Methods
Externí odkaz:
https://doaj.org/article/a5323209328e4ed08aecd39882928e15
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2023)
Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a s
Externí odkaz:
https://doaj.org/article/f845a0e0b3e643c9938201677ca3dcd6
Autor:
Caiyun Nie, Weifeng Xu, Huifang Lv, Xiaohui Gao, Guofeng Li, Beibei Chen, Jianzheng Wang, Yingjun Liu, Jing Zhao, Yunduan He, Saiqi Wang, Xiaobing Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: There is currently still a lack of effective therapeutic manner after the failure of first-line therapy for patients with advanced or metastatic gastric cancer. The present study aimed to evaluate the clinical efficacy and safety of diffe
Externí odkaz:
https://doaj.org/article/715dc75d33e245a08a0175713c36821d
Autor:
Weifeng Xu, Caiyun Nie, Huifang Lv, BeiBei Chen, Jianzheng Wang, Saiqi Wang, Jing Zhao, Yunduan He, Xiaobing Chen
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Based on increasing research evidence, hepatocellular carcinoma (HCC) is heterogeneous, and genetic profiling has led to the identification of multiple subtypes of this disease. To advance our knowledge and the ability to use individualized medicine
Externí odkaz:
https://doaj.org/article/598e63d6b99f449ab79f37922b929a3e
Autor:
Caiyun Nie, Huifang Lv, Beibei Chen, Weifeng Xu, Jianzheng Wang, Yingjun Liu, Saiqi Wang, Jing Zhao, Yunduan He, Xiaobing Chen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivesThe antitumor activity of nivolumab plus regorafenib in colorectal cancer from a phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate the efficacy and safety of regorafenib or fruquintinib plus sintilimab as t
Externí odkaz:
https://doaj.org/article/be1252b4efe5496c88e802949ce315b9